Results 51 to 60 of about 30,982 (215)

Durability of immune responses to the BNT162b2 mRNA vaccine

Med, 2022
Antibody responses to the Pfizer-BioNTech mRNA vaccine waned substantially 6 months after the second vaccination.
Mehul S. Suthar, Prabhu S. Arunachalam, Mengyun Hu, Noah Reis, Meera Trisal, Olivia Raeber, Sharon Chinthrajah, Meredith E. Davis-Gardner, Kelly Manning, Prakriti Mudvari, Eli Boritz, Sucheta Godbole, Amy R. Henry, Daniel C. Douek, Peter Halfmann, Yoshihiro Kawaoka, Scott D. Boyd, Mark M. Davis, Veronika I. Zarnitsyna, Kari Nadeau, Bali Pulendran   +20 more
openaire   +2 more sources

Association between Reactogenicity and Immunogenicity after Vaccination with BNT162b2 [PDF]

Vaccines, 2021
It is not clear whether there is an association between adverse reactions and immune response after vaccination. Seven hundred and thirty-five vaccinees from our University Medical Center vaccination clinic provided information about sex, age and adverse reactions after first and second vaccination with BNT162b2. Adverse reactions were categorized into
Bauernfeind, Stilla, Salzberger, Bernd, Hitzenbichler, Florian, Scigala, Karolina, Einhauser, Sebastian, Wagner, Ralf, Gessner, André, Koestler, Josef, Peterhoff, David   +8 more
openaire   +3 more sources

A heterologous AZD1222 priming and BNT162b2 boosting regimen more efficiently elicits neutralizing antibodies, but not memory T cells, than the homologous BNT162b2 regimen

, 2023
Background: Comparative analyses of SARS-CoV-2-specific immune responses elicited by diverse primeboost regimens are required to establish efficient regimens for the control of COVID-19.
Jae-Hoon Ko, Yoon Soo Park, Eui Cheol Shin, Yae Jee Baek, Jin Young Ahn, Kyong Ran Peck, Jung Ho Kim, Woo-Joong Kim, Ho Cheol Jang, Jun Yong Choi, Sung-Han Kim, Youn-Jung Lee, Hye Won Jeong, Yong Chan Kim   +13 more
core   +1 more source

Adverse events reported following BNT162b2 vaccine administration.

, 2023
Adverse events reported following BNT162b2 vaccine administration.
Ameer Hohlfeld (6059231), Ntombifuthi Blose (17549600), Rudzani Muloiwa (546250), Natasha Gloeck (17549603), Yusentha Balakrishna (5797361), Andy Parrish (4955884), Karen Cohen (415951), Ruth Lancaster (17549606), Sumayyah Ebrahim (846653), Andy Gray (482821), Tamara Kredo (417544)   +10 more
core   +1 more source

A racing heart post‐Pfizer/BioNTech BNT162b2

Journal of Arrhythmia, 2022
Palpitations is one of the most common side effects experienced post-messenger-RNA COVID-19 vaccines. However, some patients experience significant symptoms and further workup needs to be considered. We present an interesting case of inappropriate sinus tachycardia in a fit gentleman who presented with worsening palpitations and elevated heart rate ...
Hooi Khee Teo, Kah Leng Ho, Boon Yew Tan, Chi Keong Ching, Daniel Thuan Tee Chong   +4 more
openaire   +3 more sources

Persistence of Anti-SARS-CoV-2 Spike IgG Antibodies Following COVID-19 Vaccines

Infection and Drug Resistance, 2022
Naif Khalaf Alharbi,1,2 Jaffar A Al-Tawfiq,3– 5 Amal Alwehaibe,1 Mohamed W Alenazi,1 Abdulrahman Almasoud,1 Abdullah Algaisi,6 Fahad A Alhumaydhi,7 Anwar M Hashem,8,9 Mohammed Bosaeed,1,2,10 Suliman A Alsagaby11 1Vaccine Development Unit, King Abdullah ...
Alharbi NK, Al-Tawfiq JA, Alwehaibe A, Alenazi MW, Almasoud A, Algaisi A, Alhumaydhi FA, Hashem AM, Bosaeed M, Alsagaby SA   +9 more
doaj  

Preliminary evidence on the safety profile of BNT162b2 (Comirnaty): new insights from data analysis in EudraVigilance and adverse reaction reports from an Italian health facility

Human Vaccines & Immunotherapeutics, 2021
The first vaccine against SARS-CoV-2 made available in Italy has been BNT162b2, the two-dose mRNA-based vaccine developed by Pfizer-BioNTech. The ASST Fatebenefratelli-Sacco hospital is located in one of the areas most affected by the pandemic, and to ...
Michele Gringeri, Giulia Mosini, Vera Battini, Gianluca Cammarata, Greta Guarnieri, Carla Carnovale, Emilio Clementi, Sonia Radice   +7 more
doaj   +1 more source

Immunogenicity, safety and reactogenicity of heterologous (third dose) booster vaccination with a full or fractional dose of two different COVID-19 vaccines: A phase 4, single-blind, randomized controlled trial in adults

Human Vaccines & Immunotherapeutics, 2023
In this phase 4 study we assessed boosting with fractional doses of heterologous COVID-19 vaccines in Brazilian adults primed with two doses of CoronaVac (Sinovac/Butantan, São Paulo, Brazil) at least 4 months previously.
Sue Ann Costa Clemens, Natalie Marchevsky, Sarah Kelly, Sally Felle, Ahmed Eldawi, Rupetha Rajasingam, Rawan Mahmud, Teresa Lambe, Merryn Voysey, Isabela Gonzalez, Eveline Pipolo Milan, Maria Cleonice Justino, Sagida Bibi, Parvinder Aley, Ralf Clemens, Andrew J. Pollard   +15 more
doaj   +1 more source

The Influence of Two Priming Doses of Different Anti-COVID-19 Vaccines on the Production of Anti-SARS-CoV-2 Antibodies After the Administration of the Pfizer/BioNTech Booster

Infection and Drug Resistance, 2022
Blanka Wolszczak Biedrzycka,1,2 Anna Bieńkowska,1,2 Elwira Smolińska-Fijołek,3 Grzegorz Biedrzycki,4 Justyna Dorf5 1Department of Psychology and Sociology of Health and Public Health, University of Warmia and Mazury in Olsztyn ...
Wolszczak Biedrzycka B, Bieńkowska A, Smolińska-Fijołek E, Biedrzycki G, Dorf J   +4 more
doaj  

Evaluation of the QuantiFERON SARS-CoV-2 assay to assess cellular immunogenicity of the BNT162b2 mRNA COVID-19 vaccine in individuals with low and high humoral response

Human Vaccines & Immunotherapeutics, 2021
Vaccines against SARS-CoV-2 are known to be less immunogenic for some individuals, whereas others present notably high levels of antibody production.
Areti Tychala, Georgios Meletis, Eugenia Katsimpourlia, Ioanna Gkeka, Rodoula Dimitriadou, Eleni Sidiropoulou, Lemonia Skoura   +6 more
doaj   +1 more source